A total of 9% of placebo recipients contracted COVID-19 from a household member, compared with 3% of ensitrelvir recipients, ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

UVA School of Medicine emeritus professor Dr. Frederick G. Hayden helped design the trial and presented the results Wednesday ...

The pill, an antiviral drug called molnupiravir, was tested against a placebo in people at high risk of developing severe disease. Of the 377 people who got the placebo, 14.1 percent, or 53 ...

The Food and Drug Administration has authorized pills to treat COVID-19. The agency issued emergency approval on Wednesday for an antiviral developed by Pfizer. The FDA's authorization allows high ...

Scientists have found that an oral antiviral drug successfully prevents monkeys from dying after an Ebola infection, an ...

What have been the guiding principles in these achievements and what might the future hold for antiviral drug development? In the late 1970s, the discovery that acyclic nucleoside analogues ...

Our interviewees this month describe the rewards and challenges of their complementary roles in antiviral drug discovery and development. Joseph Vacca, Ph.D. Executive Director, Medicinal ...

Creative Diagnostics has announced its comprehensive Drug Discovery Services for antiviral therapeutic development. NEW YORK, NY, UNITED ST ...

Yesterday, SIGA Technologies, makers of the antiviral drug TPOXX (tecovirimat), announced that it has received $13 million in procurement orders for the drug, including two new international ...

Merck (MRK) is reportedly planning to double the production of molnupiravir, an antiviral COVID pill, next year. The Financial Times reported the drugmaker has secured deals to provide COVID ...